Xeomin is free from complexing proteins

Toxicon

Volumn 54, Issue 5, 2009, Pages 697-701

  Frevert, Jürgen ^a  

^a Merz Pharmaceuticals GmbH   (Germany)

Author keywords

Botulinum toxin; ; Complexing proteins efficacy

Indexed keywords

BOTULINUM TOXIN A; HEMAGGLUTININ; LECTIN; NERVE CELL ADHESION MOLECULE;

ANTIBODY TITER; ANTIGENICITY; ARTICLE; BLEPHAROSPASM; CERVICAL DYSTONIA; CLINICAL TRIAL; DRUG DETERMINATION; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG STABILITY; DRUG STORAGE; DYSPHAGIA; HUMAN; IMMUNOSTIMULATION; LD 50; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERMOSTABILITY; TORTICOLLIS;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; DRUG CONTAMINATION; NEUROMUSCULAR AGENTS;

EID: 68849115452     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.03.010     Document Type: Article

References (9)

1. Benecke R., Jost W.H., Kanovsky P., Ruzicka E., Comes G., and Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 11 (2005) 1949-1951
2. Carli L., Montecucco C., and Rossetto O. An histological assessment of diffusion of different botulinum neurotoxin type A formulations injected in the mice leg. Toxicon 51 Suppl. 1 (2008) 9
3. ®. Toxicon 51 Suppl. 1 (2008) 10
4. Eisele K.-H., and Taylor H.V. Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions. Toxicon 51 Suppl. 1 (2008) 10
5. ® is stable without refrigeration: complexing proteins are not required for stability of botulinum neurotoxin type A preparations. Toxicon 51 Suppl. 1 (2008) 13
6. Jost W.H., Blümel J., and Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 67 (2007) 669-683
7. Lee J.C., Yokota K., Arimitsu H., Hwang H.J., Sakaguchi Y., Cui J., Takeshi K., Watanabe T., Ohyama T., and Oguma K. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 151 (2005) 3739-3747
8. Roggenkämper P., Jost W.H., Bihari K., Comes G., and Grafe S. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J. Neural Transm. 113 (2006) 303-312
9. Wohlfarth K., Müller C., Sassin I., Comes G., and Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin. Neuropharmacol. 30 (2007) 86-94